{"table_id": "pone-0112638-t001", "table_label": "Table 1", "table_caption": "Demographic and clinical data of control subjects and patients with PD, MSA and PSP.", "table_foot": "*For patients taking levodopa drug treatment, scores given in the \u2018on\u2019 state.\u2020From Parkinson\u2019s Plus Scale (Cerebellar Score, maximum 24; Occulomotor Score, maximum 21).MSA\u200a=\u200amultiple systems atrophy; PSP\u200a=\u200aprogressive supranuclear palsy; PD\u200a=\u200aParkinson\u2019s disease; MSA-P\u200a=\u200amultiple system atrophy parkinsonian variant; MSA-C\u200a=\u200amultiple system atrophy cerebellar variant; H&Y\u200a=\u200aHoehn and Yahr; ADL\u200a=\u200aactivities of daily living; UPDRS III\u200a=\u200aUnified Parkinson Disease Rating Scale\u2013part III; MMSE\u200a=\u200aMini Mental State Examination; DRS\u200a=\u200aMattis Dementia Rating Scale.", "n_header_rows": 1, "table_data_file": "table_000.csv"}